PRTK News and Press, Paratek Pharmaceuticals Inc. From 02/25/21

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q4 2020 Earnings Call Feb 24, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q4 2020 Earnings Call Transcript

Paratek Pharmaceuticals, Inc. (PRTK) Q4 2020 Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants Ben Strain - Vice President of Investor Relations Evan Loh - Chief Executive Officer Adam Woodrow - President and Chief Commercial Officer Randy Brenner - Chief Development ...

The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Paratek Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Paratek Pharmaceuticals (PRTK): Q4 GAAP EPS of -$0.54 misses by $0.45.Revenue of $16.02M (+78.6% Y/Y) misses by $18.02M.2021 Guidance: Total revenue of $166 to $177M; NUZYRA net U.S. product sales ~$138 to $144M; U.S. net product sales $62 to $68M;...

-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021 -- Paratek Expects Full Year 2021 Total Revenue Between $166 and $177 Mi...

BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...

BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company that develops and commercializes life-saving therapies for public health threats in the community, hospital, and military settings, today announced the expansion of the Compan...

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. Ocumension Therapeutics inv...

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...